<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560193</url>
  </required_header>
  <id_info>
    <org_study_id>CLEAN2</org_study_id>
    <nct_id>NCT03560193</nct_id>
  </id_info>
  <brief_title>Randomized Trial of 2% Chlorhexidine-70% Isopropanol vs 5% Povidone Iodine-69% Ethanol for Skin Antisepsis in Reducing Surgical-site Infection After Cardiac Surgery</brief_title>
  <acronym>CLEAN2</acronym>
  <official_title>An Open Label, Multicenter, Randomized Trial of 2% Chlorhexidine-70% Isopropanol vs 5% Povidone Iodine-69% Ethanol for Skin Antisepsis in Reducing Surgical-site Infection After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite completion of more than 9 million procedures each year in France, the best antiseptic
      solution to be used for preparing the skin to reduce risk of surgical site infection (SSI)
      remains unknown. 2% Chlorhexidine gluconate (CHG)-alcohol is superior to Povidone Iodine
      (PVI)-alcohol for short term vascular catheter care (Mimoz O, Lancet 2015; Pages J, Intensive
      Care Med 2016), but studies comparing both antiseptic solutions for clean-contaminated
      surgical procedures led to conflicting results.

      The present study will be the first large scale multicenter randomized controlled trial
      adequately powered to compare efficacy and safety of CHG-alcohol over PVI-alcohol in reducing
      SSI after clean surgery.

      A clean surgery was chosen because pathogens involved in SSI mostly originate from skin.
      Therefore, optimisation of skin disinfection before surgery has the potential to reduce the
      incidence of SSI. Cardiac surgery was chosen because SSI may be severe, diagnosis of SSI is
      easy to monitor and to define and infections arise earlier than other frequent clean
      surgeries using implants such as orthopaedic or vascular surgery.

      The incidence of reoperation for any purpose will be used as the main objective because there
      are easy to track and define and are less susceptible to interpretation in an open trial than
      superficial SSI. According to CDC criteria, patients will be monitored up to Day 90 because
      mediastinitis after cardiac surgery may occur after the usual 30-day SSI surveillance period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of any re-sternotomy occurring between Day 0 and Day 90 after surgery</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of any reoperation on saphen venous/radial artery site occurring between Day 0 and Day 30 after surgery.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of mediastinitis according to CDC criteria occurring by Day 90 after surgery and pathogens involved</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of deep incisional SSIs at saphen venous/radial artery site according to CDC criteria occurring by Day 30 after surgery and pathogens involved</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of superficial incisional SSIs at sternal or saphen venous/radial artery sites according to CDC criteria occurring by Day 30 after surgery and pathogens involved</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SWI requiring reoperation, occurring by Day 90</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SSIs at saphen venous/radial artery site requiring reoperation, occurring by Day 30</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of unexpected need for re-admission to the ICU or re-hospitalisation</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in ICU</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days under mechanical ventilation</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in Hospital</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in rehabilitation unit</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at Day 90 of surgery</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of local and systemic side effects possibly linked to antiseptic use</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic analysis including cost-effectiveness of surgical skin antisepsis</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4100</enrollment>
  <condition>Cardiac Surgery in Adult Patient</condition>
  <arm_group>
    <arm_group_label>Chlorhexidine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Povidone Iodine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2%Chlorhexidine-70%Isopropanol</intervention_name>
    <description>2% Chlorhexidine-70% isopropanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes</description>
    <arm_group_label>Chlorhexidine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5%Povidone Iodine- 69%Ethanol</intervention_name>
    <description>5%Povidone Iodine- 69%Ethanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes</description>
    <arm_group_label>Povidone Iodine Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (age â‰¥ 18 years)

          -  Undergoing any (scheduled) surgery of the heart (valve, coronary or combined surgery)
             or of the aorta via a median sternotomy

          -  Having given their informed consent

        Exclusion Criteria:

          -  Patients with known allergies to CHG, PVI, isopropanol or ethanol

          -  Surgery for heart transplantation

          -  Any signs of inflammation or sternal instability at the site of sternotomy or
             operation for infection (SWI or endocarditis)

          -  Patients with history of cardiac surgery within 3 months preceding enrolment

          -  Participation to another clinical trial aimed at reducing SSI

          -  Patients already enrolled in this study

          -  Pregnant or breastfeeding women

          -  Women at age to procreate and not using effective contraception

          -  Patients not benefiting from a Social Security scheme or not benefiting from it
             through a third party

          -  Persons benefiting from enhanced protection, namely minors, persons deprived of their
             liberty by a judicial or administrative decision, adults under legal protection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier MIMOZ, Professor</last_name>
    <phone>+33549444600</phone>
    <email>olivier.mimoz@chu-poitiers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu BOISSON, Hospital Practitioner</last_name>
    <phone>+33549444635</phone>
    <email>matthieu.boisson@chu-poitiers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel Camilleri, Professor</last_name>
      <phone>+33473751576</phone>
      <email>lcamilleri@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christian Roussel, Professor</last_name>
      <phone>+33240165084</phone>
      <email>jeanchristian.roussel@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Bertrand Rozec, Professor</last_name>
      <phone>+33240165304</phone>
      <email>bertrand.rozec@chu-nantes.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>La PitiÃ© SalpÃ©triÃ¨re Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Demondion, Hospital Practitioner</last_name>
      <phone>+33142160000</phone>
      <email>pierre.demondion@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques-Yves Nizou, Hospital Practitioner</last_name>
      <phone>+33156616069</phone>
      <email>JacquesYves.NIZOU@imm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mathieu Debauchez, Hospital Practitioner</last_name>
      <phone>+33156616556</phone>
      <email>Mathieu.DEBAUCHEZ@imm.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital of Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MIMOZ, Professor</last_name>
      <phone>+33549444600</phone>
      <email>olivier.mimoz@chu-poitiers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Matthieu BOISSON, Hospital Practitioner</last_name>
      <phone>+33549444635</phone>
      <email>matthieu.boisson@chu-poitiers.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Nesseler, Hospital Practitioner</last_name>
      <phone>+33299284321</phone>
      <email>nicolas.nesseler@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul-Michel Mertes, MD</last_name>
      <phone>+33 3 69 55 04 46</phone>
      <email>paul-michel.mertes@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FranÃ§ois Labaste, MD</last_name>
      <phone>+33 5 61 32 28 22</phone>
      <email>labaste.f@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin antisepsis</keyword>
  <keyword>Chlorhexidine</keyword>
  <keyword>Povidone Iodine</keyword>
  <keyword>Surgical site infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

